Halozyme Therapeutics, Inc. (NASDAQ:HALO)‘s stock had its “underperform” rating reaffirmed by equities researchers at Jefferies Group LLC in a research note issued to investors on Thursday. They currently have a $7.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $6.75. Jefferies Group LLC’s target price points to a potential downside of 44.66% from the company’s previous close.

A number of other brokerages have also weighed in on HALO. BidaskClub upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Barclays PLC restated an “overweight” rating and issued a $16.00 target price on shares of Halozyme Therapeutics in a research note on Friday, June 23rd. Zacks Investment Research upgraded Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, May 12th. Canaccord Genuity set a $16.00 target price on Halozyme Therapeutics and gave the company a “buy” rating in a research note on Wednesday, July 26th. Finally, BMO Capital Markets began coverage on Halozyme Therapeutics in a research note on Monday, April 17th. They issued a “market perform” rating and a $14.00 target price for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $14.88.

Halozyme Therapeutics (HALO) opened at 12.65 on Thursday. Halozyme Therapeutics has a 12 month low of $8.18 and a 12 month high of $15.20. The company’s market cap is $1.63 billion. The company has a 50-day moving average of $13.28 and a 200-day moving average of $13.12.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.02. The business had revenue of $33.80 million during the quarter, compared to analyst estimates of $31.76 million. During the same quarter last year, the business posted ($0.21) earnings per share. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. Analysts predict that Halozyme Therapeutics will post ($0.98) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Halozyme Therapeutics’ (NASDAQ:HALO) “Underperform” Rating Reaffirmed at Jefferies Group LLC” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.watchlistnews.com/halozyme-therapeutics-nasdaqhalo-underperform-rating-reaffirmed-at-jefferies-group-llc/1467519.html.

A number of hedge funds have recently made changes to their positions in HALO. IFP Advisors Inc raised its stake in shares of Halozyme Therapeutics by 1.6% in the second quarter. IFP Advisors Inc now owns 14,686 shares of the biopharmaceutical company’s stock worth $188,000 after buying an additional 226 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Halozyme Therapeutics by 2.8% in the first quarter. Principal Financial Group Inc. now owns 20,602 shares of the biopharmaceutical company’s stock worth $267,000 after buying an additional 558 shares during the last quarter. IFC Holdings Incorporated FL raised its stake in shares of Halozyme Therapeutics by 0.7% in the first quarter. IFC Holdings Incorporated FL now owns 82,250 shares of the biopharmaceutical company’s stock worth $1,063,000 after buying an additional 600 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Halozyme Therapeutics by 1.0% in the first quarter. Janney Montgomery Scott LLC now owns 84,874 shares of the biopharmaceutical company’s stock worth $1,100,000 after buying an additional 877 shares during the last quarter. Finally, Prudential Financial Inc. raised its stake in shares of Halozyme Therapeutics by 8.7% in the second quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 940 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.